PET PHARM BIOTECH CO., LTD.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
1. Fluorodeoxyglucose injection(¹⁸F-FDG)
2. ¹⁸F-NaF
3. ¹⁸F-NaF
4. 131I capsule
2. ¹⁸F-NaF
3. ¹⁸F-NaF
4. 131I capsule
The content above was translated by Ai
Founded Year
2011
Unified Business No.
53541504
Status
Active
Number of Employees
0
Total Paid-in
Capital
580,913,340 (NT$)
Location of Company
Taiwan
, New Taipei City
Exit Status
Emerging Stock Exchange(2025)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Since its establishment, Gison Biotech has been dedicated to the research, development, and production of radiopharmaceuticals, providing high-quality medical solutions to patients nationwide. We strive to be the best partner for nuclear medicine physicians and patients alike. Our vision is to advance precision treatment in nuclear medicine, improve patient health, and become a leader in the radiopharmaceutical field both in Taiwan and globally. With innovation, quality, and service at our core, we are committed to driving the future of radiopharmaceuticals forward.
The content above was translated by Ai
